Welcome reception

Introduction & Meeting Objectives
John Gribben

Session 1:  T-cell Leukemia/Lymphoma
Chairs: Laurence de Leval & Francine Foss

 

Special Lecture: T-cell Leukemia/Lymphoma

• Pre-clinical models for precision therapy in TCLs; Francois Lemonnier
• Epidemiology and novel biomarkers of relapse refractory T-cell lymphoma; Salvia Jain
• Pathology classification and recent advances, if we want to put a focus on PTCL ; Joan Guitart
• Aggressive T-cell lymphoma in refractory patients; Francine Foss
• Epigenetic therapies in PTCLs; Enrica Marchi
• Evolving therapies in TCL (CAR-T, BsAbs, VALEMETOSTAT & VALENTINE); Robert Stuver

 

Panel Discussion

Break

Session 2: Session II:  MCL
Chairs: Stephen Ansell & Kami Maddocks

 

• Frontline therapy for MCL – which patient needs which initial regimen? Kami Maddocks
• Consolidation after frontline therapy – is autologous stem cell transplantation for MCL a thing of the past?; Kristi Blum
• How to use MRD to manage MCL; Tim Fenske
• Small molecule inhibitors for relapsed MCL – one at a time or all together? Mark Roschewski

 

Panel Discussion: Remaining gaps and perspectives

Session 3: Keynote address
Chair & Introduction: John Gribben

 

Keynote speaker: Margaret Shipp 

 

Panel Discussion

Lunch

Session 4: Novel therapies I
Chairs: Jason Westin & Laurie Sehn

 

Industry Panel Discussion: Simon Rule

• Harmonized criteria for reporting of imaging in CRFs; an industry perspective;
• ODAC regulatory perspectives on CRFs in Lymphoma; Nicole Gormley (FDA)

 

Discussion:

McAbs and ADC Combinations:

• Tafasitamab combinations, Laurie Sehn
• Zilovertamab combinations; Muhit Ozcan
• Loncastuximab combinations; Juan Pablo Alderuccio
• Polatuzumab combinations; Gilles Salles
• What’s next in Mab’s and ADC’s?; Greg Nowakowski
• Finding the right combination- The value and limits of preclinical studies; Michael Green

 

Panel Discussion

Break

Session 5: Special Topic: Hodgkin’s Lymphoma
Chairs: Peter Borchmann & Phillipe Armand

 

• PD-1 Blockade – an unfinished story; Phillipe Armand
• Suggest Alex Herrera as another speaker, possibly also Jonathan Friedberg

 

Panel Discussion

Day 1 Wrap Up

Session 6: BsAb’s for NHL
Chairs: Martin Hutchings & Elisabeth Budde

 

CD3/CD20 bispecifics and their quest for ideal partners

• Mosunetuzumab; Elisabeth Budde
• Epcoritamab combinations; Barbara Eichhorst
• Glofitamab combinations; Martin Hutchings
• Plamotamab; combinations; Tycel Phillips
• Odronextamab; RajatBannerji
• AZD0486; Sameh Gaballa

 

Roundtable Discussion

 

Bispecific and trispecifics with other formats and targets

• Imvotamab; Armando López – Guillermo
• TNB 486; Ranjit Nair
• Future perspectives with bi-and trispecific antibodies; Lorenzo Falchi or Jason Westin

 

Roundtable Discussion: Future Directions 

Break

Session 7: Novel Therapies II
Chairs: Laurie Sehn & Alexey Danilov

 

BTK Inhibitors combinations:

• Zanubrutinib combinations; PL Zinzani
• Acalabrutinib combinations; Krish Patel (now at Sarah Cannon)
• Pirtobrutinib combinations; Michael Wang

 

BTK Degraders:

• BGB-16673; John Seymour
• NX-2127 and NX5948; Alexey Danilov

BCL-2 inhibitors:

• Sonrotoclax; Steve Treon
• What’s next in targeted therapy?; Sonali Smith
• Using genomics to guide therapeutic choice; David Scott

 

Roundtable Discussion

Lunch

Session 8: Expanding the CAR platform for NHL
Chairs: David Maloney & Catherine Bollard

 

Real World Data: 

• Liso-cel for DLBCL; Jeremy Abramson
• Axi-cel; Sattva Neelapu
• Tis-a-cel, Liso-cel & Axi-cel in FL; Gloria Iacoboni
• Future perspectives – where do we go from here?; Jason Westin

e-break

• Molecular Disease Monitoring in Patients with R/R B-Cell Lymphoma; Meryl Colton
• Rapcabtagene; Pere Barba
• CD20 CAR-T; Mazyar Shadman
• Multi-targeted CARs; Claire Roddie
• Allogeneic CAR-T cells: Is there a strategy moving forward?;  Fred Locke

 

Roundtable Discussion: CAR-T in the real-World Setting

Final Meeting Summary and Conclusions
Chairs: iwNHL Committee